MX2020001057A - Composiciones y metodos para tratar la galactosemia. - Google Patents

Composiciones y metodos para tratar la galactosemia.

Info

Publication number
MX2020001057A
MX2020001057A MX2020001057A MX2020001057A MX2020001057A MX 2020001057 A MX2020001057 A MX 2020001057A MX 2020001057 A MX2020001057 A MX 2020001057A MX 2020001057 A MX2020001057 A MX 2020001057A MX 2020001057 A MX2020001057 A MX 2020001057A
Authority
MX
Mexico
Prior art keywords
methods
compositions
galactosemia
treating
treating galactosemia
Prior art date
Application number
MX2020001057A
Other languages
English (en)
Inventor
Shoshana Shendelman
Original Assignee
Applied Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Therapeutics Inc filed Critical Applied Therapeutics Inc
Publication of MX2020001057A publication Critical patent/MX2020001057A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La exposición se refiere a métodos para tratar galactosemia y manifestaciones de galactosemia utilizando inhibidores de aldosa reductasa.
MX2020001057A 2017-07-28 2018-07-27 Composiciones y metodos para tratar la galactosemia. MX2020001057A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762538443P 2017-07-28 2017-07-28
PCT/US2018/044199 WO2019023648A1 (en) 2017-07-28 2018-07-27 COMPOSITIONS AND METHODS FOR TREATING GALACTOSEMIA

Publications (1)

Publication Number Publication Date
MX2020001057A true MX2020001057A (es) 2020-11-24

Family

ID=65039851

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020001057A MX2020001057A (es) 2017-07-28 2018-07-27 Composiciones y metodos para tratar la galactosemia.
MX2022015186A MX2022015186A (es) 2017-07-28 2020-01-27 Composiciones y metodos para tratar la galactosemia.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022015186A MX2022015186A (es) 2017-07-28 2020-01-27 Composiciones y metodos para tratar la galactosemia.

Country Status (13)

Country Link
US (2) US11590131B2 (es)
EP (1) EP3658142B1 (es)
JP (2) JP7307059B2 (es)
CN (1) CN111065392A (es)
AU (2) AU2018307964B2 (es)
BR (1) BR112020001755A2 (es)
CA (1) CA3071114A1 (es)
DK (1) DK3658142T3 (es)
IL (1) IL272246A (es)
MX (2) MX2020001057A (es)
RU (1) RU2020107188A (es)
SG (1) SG11202000730QA (es)
WO (1) WO2019023648A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020001057A (es) * 2017-07-28 2020-11-24 Applied Therapeutics Inc Composiciones y metodos para tratar la galactosemia.
CA3131792C (en) * 2019-02-28 2024-04-16 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Salt of aldose reductase inhibitor, and preparation method and application thereof
EP3947391A1 (en) * 2019-04-01 2022-02-09 Applied Therapeutics Inc. Inhibitors of aldose reductase
CN114667139A (zh) * 2019-10-08 2022-06-24 应用治疗公司 用于治疗磷酸甘露变位酶2缺乏的醛糖还原酶抑制剂
BR112022021845A2 (pt) * 2020-05-01 2022-12-20 Applied Therapeutics Inc Inibidores de aldose redutase para tratar deficiência em sorbitol desidrogenase

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0189272A3 (en) 1985-01-17 1987-08-19 Fujisawa Pharmaceutical Co., Ltd. New furanone derivatives, processes for preparation thereof and use thereof
EP0222576B1 (en) 1985-11-07 1992-03-18 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
US4939140A (en) * 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
CA1299178C (en) 1985-11-07 1992-04-21 Banavara Lakshmana Mylari Heterocyclic oxophtalazinyl acetic acids
AU7386887A (en) 1986-06-12 1987-12-17 American Home Products Corporation Method of stimulating the immune system with tolrestat;(n-((5 -(trifluoromethyl)-6-methoxy-1-naphthenyl)thioxomethyl)-n-me hylglycine)
US4868301A (en) 1987-06-09 1989-09-19 Pfizer Inc. Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
CA1307537C (en) 1987-12-23 1992-09-15 Jay E. Wrobel N-naphthoylglycines as aldose reductase inhibitors
WO1989006651A1 (en) 1988-01-19 1989-07-27 Pfizer Inc. 1h-indazole-3-acetic acids as aldose reductase inhibitors
US4954629A (en) 1989-05-11 1990-09-04 Pfizer Inc. Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof
US4996204A (en) 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
FR2647676A1 (fr) 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
US5304557A (en) 1989-12-15 1994-04-19 Pfizer Inc. Substituted oxoophthalazinyl acetic acids and analogs thereof
JPH0495025A (ja) 1990-08-08 1992-03-27 Asahi Chem Ind Co Ltd アルドースリダクターゼ阻害剤
EP0662962A1 (en) 1992-09-28 1995-07-19 Pfizer Inc. Substituted pyrimidines for control of diabetic complications
US5464961A (en) 1993-09-10 1995-11-07 Olin Corporation Arcjet anode
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
IL113112A (en) 1994-03-28 2000-06-01 Nissan Chemical Ind Ltd Pyridine substituted thiazolidinediones and pharmaceutical compositions comprising them
BR9610207A (pt) 1995-08-28 1999-02-02 American Home Prod Acidos fenóxi acéticos como inibidores da aldose redutase e agentes anti-hiperglicêmicos
PL179170B1 (pl) 1995-09-15 2000-07-31 Inst Lekow Nowe zwiazki,pochodne genisteiny PL PL PL PL
DE69600784T2 (de) 1995-11-20 1999-04-08 Lilly Co Eli Proteinkinase-C-Inhibitor
US6696407B1 (en) 1997-03-21 2004-02-24 The Regents Of The University Of California Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
WO1999015529A1 (en) 1997-09-23 1999-04-01 Novo Nordisk A/S MODULES OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
EP1066283B1 (en) 1998-03-31 2004-06-23 The Institutes for Pharmaceutical Discovery, Inc. Substituted indolealkanoic acids
EP0982306A3 (en) 1998-08-21 2000-07-05 Pfizer Products Inc. Polymorph of zopolrestat monohydrate
NZ514144A (en) 1999-04-01 2001-09-28 Pfizer Prod Inc Aminopyrimidines as sorbitol dehydrogenase inhibitors
JP4511655B2 (ja) 1999-08-25 2010-07-28 ユニチカ株式会社 ソルビトール脱水素酵素、それを産生する微生物およびその製造方法
US6916824B1 (en) 1999-11-12 2005-07-12 Kansas State University Research Foundation Methods of treating cataracts and diabetic retinopathy with tricyclic pyrones
US20020068740A1 (en) * 1999-12-07 2002-06-06 Mylari Banavara L. Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications
US6570013B2 (en) 2000-02-16 2003-05-27 Pfizer Inc Salts of zopolrestat
AU2002226634B2 (en) 2001-03-30 2007-01-25 Pfizer Products Inc. Pyridazinone aldose reductase inhibitors
CA2473036A1 (en) 2002-01-23 2003-07-31 Paul Leslie Ornstein Melanocortin receptor agonists
AU2003243603A1 (en) 2002-06-13 2003-12-31 Board Of Regents, The University Of Texas System Methods and compositions involving aldose reductase inhibitors
PE20040563A1 (es) 2002-06-14 2004-10-21 Takeda Pharmaceutical Compuesto de imidazol y metodo para su produccion
HUE033381T2 (en) 2003-01-31 2017-11-28 Mount Sinai School Of Medicine Of New York Univ Combination therapy for the treatment of protein deficiency disorders
US7572910B2 (en) 2003-02-20 2009-08-11 Pfizer, Inc. Pyridazinone aldose reductase inhibitors
WO2005040182A1 (ja) 2003-10-24 2005-05-06 Meiji Seika Kaisha, Ltd. 後期糖化最終生成物形成の新規阻害剤及びアルドース還元酵素阻害剤
US20070021366A1 (en) 2004-11-19 2007-01-25 Srivastava Satish K Structural-based inhibitors of the glutathione binding site in aldose reductase, methods of screening therefor and methods of use
US20110092566A1 (en) 2004-11-19 2011-04-21 Srivastava Satish K Treatment of cancer with aldose reductase inhibitors
DK2137217T3 (en) 2007-04-05 2014-03-17 Morphotek Inc Methods of inhibiting the binding of endosialin to ligands
CN101143868A (zh) 2007-09-04 2008-03-19 北京理工大学 醛糖还原酶抑制剂结构及用途
EP2065038A1 (en) 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
US20100215726A1 (en) 2009-02-25 2010-08-26 Peter Thomas Roth Compositions for Diminishing the Appearance of Wrinkles
US20130029983A1 (en) 2009-09-23 2013-01-31 Carlo Ballatore Aminothienopyridazine inhibitors of tau assembly
EP2502079B1 (en) 2009-11-20 2015-01-28 Pharnext New diagnostic tools for charcot-marie-tooth disease
US8916563B2 (en) * 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
DK3597650T3 (da) 2010-07-16 2022-11-21 Univ Columbia Aldosereduktasehæmmere og anvendelser deraf
WO2012138384A1 (en) 2010-11-15 2012-10-11 U.S. Army Medical Research And Materiel Command Field sampling kit and methods for collecting and detecting alkyl methylphosphonic acids
CN102512407B (zh) 2011-11-23 2014-05-21 中山大学 一种β-苯丙氨酸类化合物作为醛糖还原酶抑制剂的应用
WO2013123403A1 (en) 2012-02-15 2013-08-22 Sanford-Burnham Medical Research Institute Theranostics platform and methods of use
GB201205739D0 (en) 2012-03-30 2012-05-16 Ucl Business Plc Treatment of acute inflammation in the respiratory tract
EP2877214B1 (en) 2012-07-26 2019-04-24 Joslin Diabetes Center, Inc. Predicting diabetic complications
US20170362237A1 (en) 2016-06-17 2017-12-21 Banavara L. Mylari Water soluble salts of aldose reductase inhibitors for treatment of diabetic complications
CA2904334C (en) 2013-03-15 2024-02-20 Ajay Verma Assessment of labeled probes in a subject
JP6187364B2 (ja) 2014-03-31 2017-08-30 ブラザー工業株式会社 印刷装置
JP6500992B2 (ja) 2015-09-01 2019-04-17 株式会社村田製作所 コイル内蔵部品
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
CN115160339B (zh) 2016-06-21 2024-05-14 纽约市哥伦比亚大学理事会 醛糖还原酶抑制剂及其使用方法
CN110249047A (zh) 2016-11-14 2019-09-17 纪念斯隆-凯特琳癌症中心 使用源自干细胞的施旺细胞的药物发现方法
KR20190130613A (ko) 2017-03-23 2019-11-22 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
US20200131203A1 (en) 2017-04-27 2020-04-30 Applied Therapeutics, Inc. Aldose reductase inhibitors and uses thereof
MX2020001057A (es) 2017-07-28 2020-11-24 Applied Therapeutics Inc Composiciones y metodos para tratar la galactosemia.
US11329472B2 (en) 2018-07-20 2022-05-10 Texas Instruments Incorporated Methods and apparatus to prevent undesired triggering of short circuit or over current protection
EP3840740A4 (en) 2018-08-20 2022-10-05 Maggie's Pearl, LLC COMPOUNDS FOR TREATMENT OF CONGENITAL GLYCOSYLATION DISORDERS
WO2020167937A1 (en) 2019-02-12 2020-08-20 Applied Therapeutics, Inc. Methods for treating cutaneous aging
EP3947391A1 (en) 2019-04-01 2022-02-09 Applied Therapeutics Inc. Inhibitors of aldose reductase
CN113966396A (zh) 2019-05-07 2022-01-21 迈阿密大学 遗传性神经病和相关障碍的治疗和检测
CN114667139A (zh) 2019-10-08 2022-06-24 应用治疗公司 用于治疗磷酸甘露变位酶2缺乏的醛糖还原酶抑制剂
WO2021202523A1 (en) 2020-03-31 2021-10-07 Applied Therapeutics, Inc. Aldose reductase inhibitors for the treatment of acute respiratory distress syndrome, acute lung inflammation/injury, cardiac injury and anti-viral therapy
BR112022021845A2 (pt) 2020-05-01 2022-12-20 Applied Therapeutics Inc Inibidores de aldose redutase para tratar deficiência em sorbitol desidrogenase

Also Published As

Publication number Publication date
WO2019023648A1 (en) 2019-01-31
RU2020107188A (ru) 2021-08-30
JP2022188305A (ja) 2022-12-20
IL272246A (en) 2020-03-31
JP7307059B2 (ja) 2023-07-11
CA3071114A1 (en) 2019-01-31
AU2024200537A1 (en) 2024-02-15
SG11202000730QA (en) 2020-02-27
AU2018307964A1 (en) 2020-02-13
US20230346782A1 (en) 2023-11-02
US20200230139A1 (en) 2020-07-23
DK3658142T3 (en) 2024-06-24
RU2020107188A3 (es) 2022-04-13
JP2020528938A (ja) 2020-10-01
BR112020001755A2 (pt) 2020-07-21
EP3658142A1 (en) 2020-06-03
EP3658142B1 (en) 2024-04-17
CN111065392A (zh) 2020-04-24
US11590131B2 (en) 2023-02-28
AU2018307964B2 (en) 2023-11-16
EP3658142A4 (en) 2021-06-09
MX2022015186A (es) 2023-01-24

Similar Documents

Publication Publication Date Title
MX2022015186A (es) Composiciones y metodos para tratar la galactosemia.
MX2018004290A (es) Compuestos, composiciones y metodos para modular el regulador de la conductancia transmembrana de la fibrosis quistica.
IL273875A (en) Methods and compounds for inhibiting expression of LDHA
MX2020003702A (es) Ciclopropilaminas como inhibidores de desmetilasa especifica de lisina 1 (lsd1).
WO2014113729A8 (en) Methods of treating cholangiocarcinoma
AU2016315655A8 (en) Ochrobactrum-mediated transformation of plants
AU2016263598A8 (en) Methods and kits for treating depression
MX2016013668A (es) Inhibidores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
MX2018006632A (es) Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4).
PH12020500072A1 (en) Heterocyclic inhibitors of atr kinase
MX2020000367A (es) Inhibidores de rad51.
AU2017317563A8 (en) Detergent compositions comprising xanthan lyase variants I
MY182924A (en) Enzyme compositions and uses thereof
UY37017A (es) Inhibidores aza-bencimidazol de pad4
EP3371175A4 (en) METHOD FOR TREATING A MEDULLOBLASTOMA WITH AN EZH2 INHIBITOR
WO2012088525A3 (en) Methods for treating copd
IL251546A0 (en) Preparations and kits for enzymatic fertilization and methods of using them
AU2015311730A8 (en) CaMKII inhibitors and uses thereof
GB2569488A (en) PD-1 specific aptamers
MX2018016037A (es) Variantes de lipasa y composiciones que comprenden tensioactivo y variante de lipasa.
PH12019500479A1 (en) Compositions for treating dementia
MX2015007608A (es) Metodos y composiciones para inhibir cnksr1.
SG11202110590PA (en) Inhibitors of aldose reductase
MX2018007468A (es) Composiciones de colageno 7 y metodos para usar las mismas.
EP3561051A4 (en) COMPOSITION FOR PROMOTING PROLIFERATION OF PLURIPOTENT STEM CELLS, AND METHOD FOR PROMOTING PROLIFERATION OF PLURIPOTENT STEM CELLS